Pradžia › Lėtinė limfocitinė leukemija › Tennessee
Lėtinė limfocitinė leukemija klinikiniai tyrimai Tennessee
17 tyrimai dėl Lėtinė limfocitinė leukemija ieško dalyvių vietose Tennessee.
Miestai Tennessee
Oficialus tyrimo tekstas (anglų kalba)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
Renkami dalyviai3 fazė
Amžius 65 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT07321652Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Ballad Health Cancer Care - Kingsport, Kingsport
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-30 · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Tennessee Oncology Greco Hainsworth Centers For Research Chattanooga, Chattanooga
- Tennessee Oncology, Nashville
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-28 · NCT06943872A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Tennesse Oncology Chattanooga Downtown, Chattanooga
- Tennessee Oncology, Pllc Nashville, Nashville
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-28 · NCT05006716A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Tennessee Oncology, Pllc Nashville, Nashville
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-28 · NCT06973187A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Tennessee Oncology-Chattanooga ( Site 0045), Chattanooga
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0031), Nashville
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-24 · NCT06136559A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- SCRI Oncology Partners, Nashville
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-17 · NCT07221500Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- SCRI Oncology Partners, Nashville
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-31 · NCT07516093Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- SCRI Oncology Partners, Nashville
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-28 · NCT07520006A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Sarah Cannon Research Institute SCRI, Nashville
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-17 · NCT05254743Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
Renkami dalyviai1/2 fazė
Amžius nuo 13 iki 90 · Visoms lytims · Atnaujinta 2026-08-06 · NCT06533579A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- The West Clinic, PLLC dba West Cancer Center, Germantown
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-05-19 · NCT06588478The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Baptist Clinical Research Institute, Memphis
Renkami dalyviai1/2 fazė
Amžius nuo 12 iki 95 · Visoms lytims · Atnaujinta 2026-04-15 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Tennessee Oncology, Nashville
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-20 · NCT04830137A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Tennessee Oncology, Nashville
Renkami dalyviai4 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-02 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Tennessee Oncology, Nashville
Renkami dalyviai4 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-02 · NCT06876649HPC Offered for PRESERVE Expansion
- Tristar Centennial Medical Center, Nashville
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 12 iki 80 · Visoms lytims · Atnaujinta 2025-08-28 · NCT07145411Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.